Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ANDRAE VANDROSS

Allopathic & Osteopathic Physicians Internal Medicine Medical Oncology

NPI
1205079373
CMS profile
2789901
Location
AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$175.94

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Honoraria $150.00 1
Education $25.94 2

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Alexion Pharmaceuticals, Inc. $150.00 1
PFIZER INC. $25.94 2

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ANDRAE VANDROSS

NPI 1205079373 · CMS profile ID 2789901

Allopathic & Osteopathic Physicians / Internal Medicine / Medical Oncology

AUSTIN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1205079373?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1205079373?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1205079373?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ANDRAE VANDROSS, NPI 1205079373, CMS profile ID 2789901, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1205079373?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $175.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Alexion Pharmaceuticals, Inc. $150.0006/27/2019 Honoraria No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 730071101 CMS
PFIZER INC. $14.8903/19/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672727471 CMS
PFIZER INC. $11.0503/19/2019 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672728481 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $175.94 3
PY2020 $44.69 3
PY2021 $107.19 6
PY2022 $430.20 11
PY2023 $385.16 4
PY2024 $1,083.01 10
PY2025 $3,168.19 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $874,433.33 238
PY2024 Principal investigator $413,921.09 482
PY2023 Principal investigator $420,700.05 715
PY2022 Principal investigator $499,990.99 172
PY2021 Principal investigator $187,276.47 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

238 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $1,200.00 12/31/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
A Global First-in-Human Study in NSCLC, HNSCC and Solid Tumors with Azirkitug (ABBV-514) as a Single Agent and in Combination with Budigalimab or Bevacizumab No dispute reported 06/30/2026 1202532412
Principal investigator 1 Deciphera Pharmaceuticals Inc. $630.00 12/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235977199
Principal investigator 1 Deciphera Pharmaceuticals Inc. $150.00 12/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235977203
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977135
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,280.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977138
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,607.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977142
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,344.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977146
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977151
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,280.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977154
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,607.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977158
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,344.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977162
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977165
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,280.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977169
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,607.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977174
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,344.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977178
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,280.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977182
Principal investigator 1 Deciphera Pharmaceuticals Inc. $6,381.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977185
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,607.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977188
Principal investigator 1 Deciphera Pharmaceuticals Inc. $4,344.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977192
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,009.00 12/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235977196
Principal investigator 1 Deciphera Pharmaceuticals Inc. $138.00 12/10/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235976864
Principal investigator 1 Deciphera Pharmaceuticals Inc. $84.00 12/10/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235976870
Principal investigator 1 Deciphera Pharmaceuticals Inc. $629.00 12/10/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235976874
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,745.00 12/10/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235976878
Principal investigator 1 Deciphera Pharmaceuticals Inc. $666.00 12/10/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235976882
Principal investigator 1 Exelixis Inc. $6,826.95 12/10/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382556
Principal investigator 1 Exelixis Inc. $2,859.30 11/28/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382542
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,260.00 11/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976382
Principal investigator 1 Deciphera Pharmaceuticals Inc. $150.00 11/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976385
Principal investigator 1 Exelixis Inc. $1,671.30 11/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382562
Principal investigator 1 ABBVIE INC. $150.00 11/26/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202525410
Principal investigator 1 ABBVIE INC. $437.40 11/19/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202524594
Principal investigator 1 ABBVIE INC. $437.40 11/19/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202524596
Principal investigator 1 ABBVIE INC. $874.80 11/19/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202524598
Principal investigator 1 Exelixis Inc. $59.40 11/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382620
Principal investigator 1 Deciphera Pharmaceuticals Inc. $150.00 11/13/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976113
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,000.00 11/12/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976021
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,000.00 11/12/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976024
Principal investigator 1 Deciphera Pharmaceuticals Inc. $24,750.00 11/12/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235976028
Principal investigator 1 Servier BioInnovation $1,451.25 11/12/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972406
Principal investigator 1 Servier BioInnovation $1,316.25 11/12/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972410
Principal investigator 1 ABBVIE INC. $75.00 11/05/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202521257
Principal investigator 1 ABBVIE INC. $75.00 11/05/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202521259
Principal investigator 1 ABBVIE INC. $75.00 11/05/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202521269
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,960.00 11/03/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975766
Principal investigator 1 ABBVIE INC. $5,782.05 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202518879
Principal investigator 1 ABBVIE INC. $5,782.05 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202518881
Principal investigator 1 ABBVIE INC. $2,511.00 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202518887
Principal investigator 1 ABBVIE INC. $1,601.10 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202518889
Principal investigator 1 ABBVIE INC. $1,601.10 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202518963
Principal investigator 1 ABBVIE INC. $5,782.05 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202518965
Principal investigator 1 ABBVIE INC. $4,758.75 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202518967
Principal investigator 1 ABBVIE INC. $3,041.55 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202518999
Principal investigator 1 ABBVIE INC. $3,577.50 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519001
Principal investigator 1 ABBVIE INC. $4,758.75 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519021
Principal investigator 1 ABBVIE INC. $1,601.10 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519023
Principal investigator 1 ABBVIE INC. $1,601.10 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519025
Principal investigator 1 ABBVIE INC. $2,511.00 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519027
Principal investigator 1 ABBVIE INC. $1,601.10 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519029
Principal investigator 1 ABBVIE INC. $4,313.25 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519197
Principal investigator 1 ABBVIE INC. $6,166.80 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519201
Principal investigator 1 ABBVIE INC. $4,023.00 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519207
Principal investigator 1 ABBVIE INC. $4,758.75 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519217
Principal investigator 1 ABBVIE INC. $1,601.10 10/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202519389
Principal investigator 1 Exelixis Inc. $6,826.95 10/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382540
Principal investigator 1 Exelixis Inc. $1,863.00 10/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382546
Principal investigator 1 Exelixis Inc. $6,462.45 10/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382552
Principal investigator 1 Exelixis Inc. $1,863.00 10/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382572
Principal investigator 1 Exelixis Inc. $6,462.45 10/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382596
Principal investigator 1 Exelixis Inc. $2,953.80 10/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382600
Principal investigator 1 ABBVIE INC. $63.45 10/22/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202517713
Principal investigator 1 ABBVIE INC. $218.70 10/22/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202517729
Principal investigator 1 ABBVIE INC. $218.70 10/22/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202517731
Principal investigator 1 ABBVIE INC. $218.70 10/22/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202517767
Principal investigator 1 ABBVIE INC. $63.45 10/22/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202517925
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975439
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975442
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,009.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975446
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975450
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975454
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975458
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975460
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975464
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975469
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975472
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975476
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975482
Principal investigator 1 Deciphera Pharmaceuticals Inc. $584.00 10/16/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975299
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,719.80 10/15/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975284
Principal investigator 1 Deciphera Pharmaceuticals Inc. $5,960.00 10/13/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975180
Principal investigator 1 Deciphera Pharmaceuticals Inc. $666.00 10/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975036
Principal investigator 1 Deciphera Pharmaceuticals Inc. $84.00 10/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235975040
Principal investigator 1 Servier BioInnovation $300.00 10/08/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972391
Principal investigator 1 Servier BioInnovation $5,733.45 10/08/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972394
Principal investigator 1 Servier BioInnovation $4,143.15 10/08/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972398
Principal investigator 1 Servier BioInnovation $978.75 10/08/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972402
Principal investigator 1 Deciphera Pharmaceuticals Inc. $1,489.00 10/06/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235974946
Principal investigator 1 ABBVIE INC. $75.00 09/25/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202512372
Principal investigator 1 ABBVIE INC. $75.00 09/25/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202512374
Principal investigator 1 ABBVIE INC. $656.10 09/19/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202511634
Principal investigator 1 ABBVIE INC. $63.45 09/19/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202511666
Principal investigator 1 Deciphera Pharmaceuticals Inc. $3,263.76 09/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235974471
Principal investigator 1 Deciphera Pharmaceuticals Inc. $2,980.00 09/17/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A PHASE 1/2 STUDY OF DCC-3116 IN PATIENTS WITH MAPK PATHWAY MUTANT SOLID TUMORS No dispute reported 06/30/2026 1235974474
Principal investigator 1 Servier BioInnovation $4,767.53 09/10/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972364
Principal investigator 1 Servier BioInnovation $8,440.20 09/10/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972368
Principal investigator 1 Servier BioInnovation $1,652.40 09/10/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972372
Principal investigator 1 Servier BioInnovation $1,861.65 09/10/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972376
Principal investigator 1 Servier BioInnovation $1,807.65 09/10/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972380
Principal investigator 1 Servier BioInnovation $1,505.25 09/10/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972384
Principal investigator 1 Exelixis Inc. $70.00 09/01/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382198
Principal investigator 1 Exelixis Inc. $65.00 09/01/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382230
Principal investigator 1 Exelixis Inc. $70.00 09/01/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382250
Principal investigator 1 ABBVIE INC. $75.00 08/28/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202506321
Principal investigator 1 Exelixis Inc. $2,377.35 08/28/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382192
Principal investigator 1 Exelixis Inc. $1,644.30 08/28/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382224
Principal investigator 1 Deciphera Pharmaceuticals Inc. $315.00 08/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235974040
Principal investigator 1 Deciphera Pharmaceuticals Inc. $75.00 08/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235974043
Principal investigator 1 Deciphera Pharmaceuticals Inc. $315.00 08/27/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers No dispute reported 06/30/2026 1235974047
Principal investigator 1 Exelixis Inc. $3,242.70 08/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382182
Principal investigator 1 Exelixis Inc. $3,145.50 08/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382186
Principal investigator 1 Exelixis Inc. $1,863.00 08/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382238
Principal investigator 1 Exelixis Inc. $3,337.20 08/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382242
Principal investigator 1 Exelixis Inc. $6,826.95 08/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382252
Principal investigator 1 Exelixis Inc. $492.75 08/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382254
Principal investigator 1 Exelixis Inc. $2,054.70 08/21/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382258
Principal investigator 1 Exelixis Inc. $2,683.00 08/18/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382294
Principal investigator 1 Exelixis Inc. $945.00 08/18/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382298
Principal investigator 1 Exelixis Inc. $1,548.00 08/18/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382310
Principal investigator 1 Exelixis Inc. $1,500.00 08/18/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382322
Principal investigator 1 Exelixis Inc. $300.00 08/13/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382278
Principal investigator 1 Exelixis Inc. $1,500.00 08/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382306
Principal investigator 1 Exelixis Inc. $229.50 08/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382320
Principal investigator 1 Exelixis Inc. $150.00 08/06/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382194
Principal investigator 1 Exelixis Inc. $450.00 08/06/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382202
Principal investigator 1 Exelixis Inc. $450.00 08/06/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382210
Principal investigator 1 Exelixis Inc. $142.00 08/06/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382214
Principal investigator 1 Exelixis Inc. $235.00 08/06/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382226
Principal investigator 1 Exelixis Inc. $235.00 08/06/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382272
Principal investigator 1 Exelixis Inc. $537.30 07/29/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382308
Principal investigator 1 ABBVIE INC. $270.00 07/28/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202500050
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,100.00 07/24/2025 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211628725
Principal investigator 1 ABBVIE INC. $7,950.00 07/23/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202499272
Principal investigator 1 Exelixis Inc. $2,683.00 07/09/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382188
Principal investigator 1 Exelixis Inc. $945.00 07/09/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382196
Principal investigator 1 Exelixis Inc. $1,548.00 07/09/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382208
Principal investigator 1 Exelixis Inc. $1,500.00 07/09/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382268
Principal investigator 1 Servier BioInnovation $675.00 07/09/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972388
Principal investigator 1 ABBVIE INC. $75.00 07/02/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202493915
Principal investigator 1 Exelixis Inc. $307.80 07/02/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382314
Principal investigator 1 ABBVIE INC. $218.70 06/16/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202491531
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $5,100.00 06/16/2025 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211628721
Principal investigator 1 Exelixis Inc. $9,498.60 06/11/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382172
Principal investigator 1 ABBVIE INC. $1,745.00 05/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202487113
Principal investigator 1 ABBVIE INC. $437.40 05/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202487115
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $7,617.85 05/28/2025 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211628718
Principal investigator 1 Servier BioInnovation $2,147.00 05/16/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972360
Principal investigator 1 ABBVIE INC. $300.00 05/08/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202484177
Principal investigator 1 Exelixis Inc. $1,863.00 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382030
Principal investigator 1 Exelixis Inc. $492.75 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382036
Principal investigator 1 Exelixis Inc. $3,337.20 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382038
Principal investigator 1 Exelixis Inc. $2,762.10 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382070
Principal investigator 1 Exelixis Inc. $6,826.95 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382080
Principal investigator 1 Exelixis Inc. $2,054.70 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382094
Principal investigator 1 Exelixis Inc. $2,859.30 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382096
Principal investigator 1 Exelixis Inc. $2,762.10 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382098
Principal investigator 1 Exelixis Inc. $6,079.05 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382100
Principal investigator 1 Exelixis Inc. $1,671.30 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382116
Principal investigator 1 Exelixis Inc. $3,242.70 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382120
Principal investigator 1 Exelixis Inc. $3,145.50 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382150
Principal investigator 1 Exelixis Inc. $8,599.50 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382152
Principal investigator 1 Exelixis Inc. $2,953.80 05/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382156
Principal investigator 1 ABBVIE INC. $218.70 05/01/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480671
Principal investigator 1 ABBVIE INC. $218.70 05/01/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480673
Principal investigator 1 ABBVIE INC. $4,222.80 04/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480423
Principal investigator 1 ABBVIE INC. $2,511.00 04/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480425
Principal investigator 1 ABBVIE INC. $4,313.25 04/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480427
Principal investigator 1 ABBVIE INC. $1,601.10 04/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480459
Principal investigator 1 ABBVIE INC. $3,041.55 04/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480461
Principal investigator 1 ABBVIE INC. $6,166.80 04/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480487
Principal investigator 1 ABBVIE INC. $3,577.50 04/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480489
Principal investigator 1 ABBVIE INC. $1,601.10 04/30/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202480491
Principal investigator 1 ABBVIE INC. $75.00 04/16/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202476831
Principal investigator 1 Exelixis Inc. $6,826.95 04/11/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382060
Principal investigator 1 Exelixis Inc. $235.00 04/11/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382086
Principal investigator 1 Exelixis Inc. $450.00 04/11/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222382102
Principal investigator 1 Exelixis Inc. $32,491.80 04/11/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382162
Principal investigator 1 Exelixis Inc. $29,880.23 04/11/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382164
Principal investigator 1 Exelixis Inc. $519.23 04/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382174
Principal investigator 1 Exelixis Inc. $395.60 04/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382176
Principal investigator 1 Exelixis Inc. $244.56 04/08/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382178
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $2,600.00 03/28/2025 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211628709
Principal investigator 1 Exelixis Inc. $496.80 03/28/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382018
Principal investigator 1 ABBVIE INC. $75.00 03/10/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202462237
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $485.00 03/06/2025 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211628713
Principal investigator 1 Exelixis Inc. $1,863.00 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381822
Principal investigator 1 Exelixis Inc. $2,859.30 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381830
Principal investigator 1 Exelixis Inc. $6,462.45 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381834
Principal investigator 1 Exelixis Inc. $1,863.00 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381846
Principal investigator 1 Exelixis Inc. $1,863.00 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381852
Principal investigator 1 Exelixis Inc. $492.75 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381862
Principal investigator 1 Exelixis Inc. $6,462.45 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381874
Principal investigator 1 Exelixis Inc. $5,336.55 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381882
Principal investigator 1 Exelixis Inc. $6,826.95 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381888
Principal investigator 1 Exelixis Inc. $6,131.70 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381890
Principal investigator 1 Exelixis Inc. $2,859.30 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381902
Principal investigator 1 Exelixis Inc. $6,826.95 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381906
Principal investigator 1 Exelixis Inc. $2,953.80 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381916
Principal investigator 1 Exelixis Inc. $5,336.55 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381920
Principal investigator 1 Exelixis Inc. $6,131.70 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381932
Principal investigator 1 Exelixis Inc. $6,462.45 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381934
Principal investigator 1 Exelixis Inc. $6,826.95 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381982
Principal investigator 1 Exelixis Inc. $2,953.80 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381984
Principal investigator 1 Exelixis Inc. $124.20 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382006
Principal investigator 1 Exelixis Inc. $248.40 02/26/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382014
Principal investigator 1 ABBVIE INC. $2,365.00 02/24/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202453710
Principal investigator 1 Exelixis Inc. $227,005.92 02/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222381998
Principal investigator 1 Exelixis Inc. $5,000.00 02/19/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382016
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $3,670.65 02/17/2025 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211628701
Principal investigator 1 Servier BioInnovation $3,212.00 02/14/2025 Non-covered Recipient Entity
New Experimental Therapeutics of San Antonio LLC
S095035 in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of the Methylthioadenosine Phosphorylase (MTAP) Gene No dispute reported 06/30/2026 1235972414
Principal investigator 1 Exelixis Inc. $150.00 02/06/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of the Safety and Pharmacokinetics of XB002 in Subjects with Inoperable Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382026
Principal investigator 1 Chugai Pharmaceutical Co., Ltd. $1,632.15 02/05/2025 Non-covered Recipient Entity
New Experimental Therapeutics of Austin - NEXT Oncology
A phase I open-label, dose-escalation and cohort expansion study of LUNA18 monotherapy and combination therapy in patients with locally advanced or metastatic solid tumors No dispute reported 06/30/2026 1211628705
Principal investigator 1 ABBVIE INC. $4,344.30 01/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442917
Principal investigator 1 ABBVIE INC. $1,315.00 01/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442921
Principal investigator 1 ABBVIE INC. $1,155.60 01/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442924
Principal investigator 1 ABBVIE INC. $3,280.50 01/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442929
Principal investigator 1 ABBVIE INC. $2,835.00 01/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442933
Principal investigator 1 ABBVIE INC. $1,155.60 01/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442935
Principal investigator 1 ABBVIE INC. $1,155.60 01/29/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202442939
Principal investigator 1 Exelixis Inc. $450.00 01/24/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381820
Principal investigator 1 Exelixis Inc. $315.00 01/24/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381848
Principal investigator 1 Exelixis Inc. $142.00 01/24/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381856
Principal investigator 1 Exelixis Inc. $350.00 01/24/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381858
Principal investigator 1 Exelixis Inc. $235.00 01/24/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381898
Principal investigator 1 Exelixis Inc. $315.00 01/24/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381908
Principal investigator 1 Exelixis Inc. $350.00 01/24/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381986
Principal investigator 1 Exelixis Inc. $150.00 01/24/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients with Advanced Solid Tumors No dispute reported 06/30/2026 1222381988
Principal investigator 1 Exelixis Inc. $372.60 01/24/2025 Non-covered Recipient Entity
NEW EXPERIMENTAL THERAPEUTICS OF SAN ANTONIO LLC
A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors No dispute reported 06/30/2026 1222382008
Principal investigator 1 ABBVIE INC. $775.00 01/22/2025 Non-covered Recipient Entity
NEXT ONCOLOGY
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer (NSCLC) Head and Neck Squamous Cell Carcinoma (HNSCC) and Other Solid Tumors Receiving Intravenous (IV) Infusion of ABBV-514 Alone or in Combination With Pembrolizumab or Budigalimab No dispute reported 06/30/2026 1202440909